Substance P-induced lung inflammation in mice is mast cell dependent
© 2021 John Wiley & Sons Ltd..
BACKGROUND: Allergic asthma is a common inflammatory lung disease and a major health problem worldwide. Mast cells (MCs) play a key role in the early-stage pathophysiology of allergic asthma. Substance P (SP) functions in neurogenic inflammation by activating MCs, and therefore, it may to participate in the occurrence and development of asthma.
OBJECTIVE: We examined the relationship between SP and lung inflammation, and also whether SP can directly trigger asthma.
METHODS: We measured the number of peripheral blood eosinophils, neutrophils and basophils and evaluated the levels of IgE and SP in blood samples of 86 individuals with allergic asthma. Serum IgE and SP levels were also determined in 29 healthy individuals. C57BL/6 mice were subjected to different doses of SP, and bronchoalveolar lavage fluid (BALF) was collected to count the inflammatory cells. Lung tissues were analysed using histopathological methods to evaluate lung peribronchial inflammation, fibrosis and glycogen deposition. Levels of IgE, interleukin (IL)-1, IL-2, IL-4, IL-5, IL-13, IL-17 and IFN-γ were determined in mouse serum.
RESULTS: Substance P levels were increased in the serum samples of patients with asthma. SP induced mouse lung peribronchial inflammation, fibrosis and glycogen deposition, with high levels of Th2-related cytokines such as IL-4, IL-5 and IL-13 observed in the BALF. Furthermore, low level of total IgE was noted in the serum, and SP had little effect on MC-deficient kitW-sh/W-sh mice.
CONCLUSIONS & CLINICAL RELEVANCE: Substance P levels increased significantly in serum of asthmatic patients and independently associated with the risk of asthma. Furthermore, SP induced Th2 lung inflammation in mice, which was dependent on MCs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:52 |
|---|---|
| Enthalten in: |
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology - 52(2022), 1 vom: 26. Jan., Seite 46-58 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Nan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
33507-63-0 |
|---|
| Anmerkungen: |
Date Completed 31.03.2022 Date Revised 31.05.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/cea.13902 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM325507112 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM325507112 | ||
| 003 | DE-627 | ||
| 005 | 20231225192600.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/cea.13902 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1084.xml |
| 035 | |a (DE-627)NLM325507112 | ||
| 035 | |a (NLM)33999474 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, Nan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Substance P-induced lung inflammation in mice is mast cell dependent |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.03.2022 | ||
| 500 | |a Date Revised 31.05.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 John Wiley & Sons Ltd. | ||
| 520 | |a BACKGROUND: Allergic asthma is a common inflammatory lung disease and a major health problem worldwide. Mast cells (MCs) play a key role in the early-stage pathophysiology of allergic asthma. Substance P (SP) functions in neurogenic inflammation by activating MCs, and therefore, it may to participate in the occurrence and development of asthma | ||
| 520 | |a OBJECTIVE: We examined the relationship between SP and lung inflammation, and also whether SP can directly trigger asthma | ||
| 520 | |a METHODS: We measured the number of peripheral blood eosinophils, neutrophils and basophils and evaluated the levels of IgE and SP in blood samples of 86 individuals with allergic asthma. Serum IgE and SP levels were also determined in 29 healthy individuals. C57BL/6 mice were subjected to different doses of SP, and bronchoalveolar lavage fluid (BALF) was collected to count the inflammatory cells. Lung tissues were analysed using histopathological methods to evaluate lung peribronchial inflammation, fibrosis and glycogen deposition. Levels of IgE, interleukin (IL)-1, IL-2, IL-4, IL-5, IL-13, IL-17 and IFN-γ were determined in mouse serum | ||
| 520 | |a RESULTS: Substance P levels were increased in the serum samples of patients with asthma. SP induced mouse lung peribronchial inflammation, fibrosis and glycogen deposition, with high levels of Th2-related cytokines such as IL-4, IL-5 and IL-13 observed in the BALF. Furthermore, low level of total IgE was noted in the serum, and SP had little effect on MC-deficient kitW-sh/W-sh mice | ||
| 520 | |a CONCLUSIONS & CLINICAL RELEVANCE: Substance P levels increased significantly in serum of asthmatic patients and independently associated with the risk of asthma. Furthermore, SP induced Th2 lung inflammation in mice, which was dependent on MCs | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a SP | |
| 650 | 4 | |a Th2 | |
| 650 | 4 | |a asthma | |
| 650 | 4 | |a mast cell | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 650 | 7 | |a Substance P |2 NLM | |
| 650 | 7 | |a 33507-63-0 |2 NLM | |
| 700 | 1 | |a Wang, Jue |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yongjing |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Shiling |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Tianxiao |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Yuanyuan |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Xiuzhen |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Tao |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Shuanying |e verfasserin |4 aut | |
| 700 | 1 | |a He, Langchong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology |d 1990 |g 52(2022), 1 vom: 26. Jan., Seite 46-58 |w (DE-627)NLM012617121 |x 1365-2222 |7 nnns |
| 773 | 1 | 8 | |g volume:52 |g year:2022 |g number:1 |g day:26 |g month:01 |g pages:46-58 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/cea.13902 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 52 |j 2022 |e 1 |b 26 |c 01 |h 46-58 | ||